+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Synthetic Cannabinoids"

Synthetic Cannabinoids Market Report 2025 - Product Thumbnail Image

Synthetic Cannabinoids Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Cannabis Pharmaceuticals Market Report 2025 - Product Thumbnail Image

Cannabis Pharmaceuticals Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
Cannabidiol (CBD) Oil: Global Markets - Product Thumbnail Image

Cannabidiol (CBD) Oil: Global Markets

  • Report
  • August 2020
  • 139 Pages
  • Global
From
Cannabis Market: Products, Technologies and Applications - Product Thumbnail Image

Cannabis Market: Products, Technologies and Applications

  • Report
  • November 2019
  • 167 Pages
  • Global
From
The Pharmaceutical Cannabis Report: 3rd Edition - Product Thumbnail Image

The Pharmaceutical Cannabis Report: 3rd Edition

  • Report
  • August 2023
  • 58 Pages
  • Global
  • 10 Results (Page 1 of 1)
Loading Indicator

Synthetic Cannabinoids are a class of analgesic drugs that are designed to mimic the effects of cannabis. They are typically used to treat chronic pain, nausea, and other conditions. Synthetic Cannabinoids are often used in combination with other analgesics, such as opioids, to provide a more comprehensive approach to pain management. They are also used to treat conditions such as anxiety, depression, and insomnia. Synthetic Cannabinoids are generally considered to be safer than traditional cannabis products, as they are not associated with the same risks of addiction and abuse. The Synthetic Cannabinoids market is growing rapidly, as more people are turning to these drugs to manage their pain and other conditions. The market is expected to continue to expand as more research is conducted into the potential benefits of these drugs. Some of the major companies in the Synthetic Cannabinoids market include GW Pharmaceuticals, Insys Therapeutics, AbbVie, and Zynerba Pharmaceuticals. Show Less Read more